These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37476838)

  • 1. CDC42-A promising immune-related target in glioma.
    Jiang T; Wang X; Huang J; Chen D
    Front Neurosci; 2023; 17():1192766. PubMed ID: 37476838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
    Tian QS; Zhang Q; Huang W
    Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EFNA1 is a potential key gene that correlates with immune infiltration in low-grade glioma.
    Hao YP; Wang WY; Qiao Q; Li G
    Medicine (Baltimore); 2021 Jun; 100(22):e26188. PubMed ID: 34087884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MELK is a prognostic biomarker and correlated with immune infiltration in glioma.
    Yang H; Zhou H; Wang G; Tian L; Li H; Zhang Y; Xue X
    Front Neurol; 2022; 13():977180. PubMed ID: 36353126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of the novel prognostic biomarker, MLLT11, reveals its relationship with immune checkpoint markers in glioma.
    Chen L; Xiong Z; Zhao H; Teng C; Liu H; Huang Q; Wanggou S; Li X
    Front Oncol; 2022; 12():889351. PubMed ID: 36033495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
    Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
    Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepcidin is upregulated and is a potential therapeutic target associated with immunity in glioma.
    Dong T; Zhang B; Zhang R; Wang C; Liu X; Wang F; Hao N; Tan K; Chang YZ
    Front Oncol; 2022; 12():963096. PubMed ID: 36237302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The new oncogene transmembrane protein 60 is a potential therapeutic target in glioma.
    Yang F; Zhang X; Wang X; Xue Y; Liu X
    Front Genet; 2022; 13():1029270. PubMed ID: 36744183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High expression of PCOLCE gene indicate poor prognosis in patients and are associated with immune infiltration in glioma.
    Guo Q; Gao X; Li J; Liu Y; Liu J; Yang H; Cui M; Zhang M; Duan L; Ma X
    Sci Rep; 2023 Mar; 13(1):3820. PubMed ID: 36882457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MCM4 is a novel prognostic biomarker and promotes cancer cell growth in glioma.
    Yang S; Yuan Y; Ren W; Wang H; Zhao Z; Zhao H; Zhao Q; Chen X; Jiang X; Zhang L
    Front Oncol; 2022; 12():1004324. PubMed ID: 36465369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma.
    Cheng W; Li M; Jiang Y; Zhang C; Cai J; Wang K; Wu A
    J Neurosurg; 2016 Jul; 125(1):7-16. PubMed ID: 26544773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceruloplasmin is associated with the infiltration of immune cells and acts as a prognostic biomarker in patients suffering from glioma.
    Jia M; Dong T; Cheng Y; Rong F; Zhang J; Lv W; Zhen S; Jia X; Cong B; Wu Y; Cui H; Hao P
    Front Pharmacol; 2023; 14():1249650. PubMed ID: 37637428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
    Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
    BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive significance of PRR11 in prognosis and immune infiltration of glioma patients.
    Han W; Chen L
    Mol Carcinog; 2023 Jul; 62(7):975-990. PubMed ID: 37036189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune and Clinical Features of
    Zhang Q; Zhong H; Fan Y; Liu Q; Song J; Yao S; Cao F
    Front Bioeng Biotechnol; 2020; 8():592. PubMed ID: 32695752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular and clinical characterization of CD163 expression via large-scale analysis in glioma.
    Liu S; Zhang C; Maimela NR; Yang L; Zhang Z; Ping Y; Huang L; Zhang Y
    Oncoimmunology; 2019; 8(7):1601478. PubMed ID: 31143523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers].
    Liu J; Xu K; Ma L; Wang Y
    Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive analysis of m
    Zhao K; Li W; Yang Y; Hu X; Dai Y; Huang M; Luo J; Zhang K; Zhao N
    Front Immunol; 2022; 13():955848. PubMed ID: 36203569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autophagy related DNA methylation signature predict clinical prognosis and immune microenvironment in low-grade glioma.
    Qiao Q; Wang Y; Zhang R; Pang Q
    Transl Cancer Res; 2022 Jul; 11(7):2157-2174. PubMed ID: 35966301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and validation of transferrin receptor protein 1 for predicting prognosis and immune infiltration in lower grade glioma.
    Wu H; He H; Huang J; Wang C; Dong Y; Lin R; Cheng Z; Qiu Q; Hong L
    Front Mol Neurosci; 2022; 15():972308. PubMed ID: 36483569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.